Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Inclusion Criteria

• Subjects with relapsed/refractory MM who have received at least two prior lines of therapy including lenalidomide and either bortezomib or carfilzomib and have demonstrated disease progression on or within 60 days of the completion of the most recent treatment regimen.
• Measurable disease defined by at least ONE of the following:
• Serum monoclonal protein (SPEP) ≥1 g/dL.
• Urine monoclonal protein (UPEP) ≥200 mg by 24 hour urine.
• Adequate hematologic, hepatic, and renal function
• ECOG performance status of ≤ 2

Exclusion Criteria

• Subject must not have primary refractory disease
• Plasma cell leukemia, primary amyloidosis or POEMS syndrome
• Unable to swallow capsules or disease significantly affecting gastrointestinal function
• Requires treatment with strong CYP3A inhibitors
• Women who are pregnant or breast feeding.